文献速递乳腺乳腺X线

数字乳腺断层合成随机对照试验前后早期筛查结局比较

Early screening outcomes before, during, and after a randomized controlled trial with digital breast tomosynthesis.
PubMed 文献 · Eur J Radiol · 2023-09-01

该回顾性研究描述了2014-2021年四个连续筛查轮次共125,020次筛查检查的结果,比较了To-Be 1随机对照试验前(数字乳腺摄影)、期间(数字乳腺摄影或数字乳腺断层合成)、To-Be 2随访队列(数字乳腺断层合成)及To-Be 2后(数字乳腺摄影)五个队列的早期筛查结局。结果显示,在To-Be 2中使用数字乳腺断层合成筛查的女性筛查检出癌症率为0.90%,而To-Be 1前使用数字乳腺摄影为0.64%;To-Be 1数字乳腺摄影(0.61%)、To-Be 1数字乳腺断层合成(0.66%)和To-Be 2后数字乳腺摄影(0.67%)队列的筛查检出癌症率无差异。结论:在组织性人群筛查项目中,随机对照试验后对所有女性采用数字乳腺断层合成筛查显示筛查检出癌症率出现暂时性增加。

要点

  • To-Be 2数字乳腺断层合成筛查检出癌症率0.90%,高于To-Be 1前数字乳腺摄影的0.64%。
  • To-Be 1数字乳腺摄影、To-Be 1数字乳腺断层合成和To-Be 2后数字乳腺摄影的筛查检出癌症率无差异。
  • 间期癌症率范围为0.13%至0.20%,组织病理学肿瘤特征分布在队列间无差异。

核心结论

  • 在组织性人群筛查项目中,随机对照试验后对所有女性采用数字乳腺断层合成筛查显示筛查检出癌症率出现暂时性增加。

研究设计与样本

  • 回顾性研究,纳入2014-2021年四个连续筛查轮次的125,020次筛查检查,分为To-Be 1前(数字乳腺摄影)、To-Be 1(数字乳腺摄影或数字乳腺断层合成)、To-Be 2(数字乳腺断层合成)和To-Be 2后(数字乳腺摄影)五个队列。

诊断标准与关键数值

  • To-Be 2数字乳腺断层合成队列筛查检出癌症率为0.90%,To-Be 1前数字乳腺摄影队列为0.64%。
  • To-Be 1数字乳腺摄影队列筛查检出癌症率为0.61%,To-Be 1数字乳腺断层合成队列为0.66%,To-Be 2后数字乳腺摄影队列为0.67%,三者间无差异。
  • 间期癌症率范围为0.13%至0.20%。
  • 组织病理学肿瘤特征分布在队列间无差异。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: To describe and compare early screening outcomes before, during and after a randomized controlled trial with digital breast tomosynthesis (DBT) including synthetic 2D mammography versus standard digital mammography (DM) (To-Be 1) and a follow-up cohort study using DBT (To-Be 2).

METHODS: Retrospective results of 125,020 screening examinations from four consecutive screening rounds performed in 2014-2021 were described and compared for pre-To-Be 1 (DM), To-Be 1 (DM or DBT), To-Be 2 (DBT), and post-To-Be 2 (DM) cohorts. Descriptive analyses of rates of recall, biopsy, screen-detected and interval cancer, distribution of histopathologic tumor characteristics and time spent on image interpretation and consensus were presented for the four rounds including five cohorts, one cohort in each screening round except for the To-Be 1 trail, which included a DBT and a DM cohort. Odds ratios (OR) with 95% CIs was calculated for recall and cancer detection rates.

RESULTS: Rate of screen-detected cancer was 0.90% for women screened with DBT in To-Be 2 and 0.64% for DM in pre-To-Be 1. The rates did not differ for the To-Be 1 DM (0.61%), To-Be 1 DBT (0.66%) and post-To-Be 2 DM (0.67%) cohorts. The interval cancer rates ranged between 0.13% and 0.20%. The distribution of histopathologic tumor characteristics did not differ between the cohorts.

CONCLUSIONS: Screening all women with DBT following a randomized controlled trial in an organized, population-based screening program showed a temporary increase in the rate of screen-detected cancer.

来源:Eur J Radiol,查看原文。版权归原作者所有。

引用

  1. Holen ÅS, Bergan MB, Lee CI, et al. Early screening outcomes before, during, and after a randomized controlled trial with digital breast tomosynthesis. Eur J Radiol. 2023. PMID: 37708674. doi:10.1016/j.ejrad.2023.111069

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。